Prosecution Insights
Last updated: October 02, 2026

Examiner: KRIANGCHAIVECH, KETTIP

Tech Center 2800 • Art Units: 1672 1686 2863

This examiner grants 19% of resolved cases

Analysis

Kettip Kriangchaivech serves as an examiner in Art Unit 1672 within Tech Center 2800. The examiner has 56 resolved cases with an allowance rate of 19.6 percent. This low rate indicates a highly challenging environment for applicants, where the vast majority of cases do not result in a grant. The 56 resolved cases provide the current statistical basis for evaluating the examiner's rigorous approach to patentability.

The data reveals an interview lift of 29.6 percent, which is significant given the low baseline allowance rate. This 29.6 percent lift suggests that verbal communication can substantially improve the odds of reaching an agreement. The median days to allowance is 1793, reflecting a very long prosecution cycle. Practitioners should be prepared for the 1793-day median and should strongly consider scheduling interviews to overcome the 19.6 percent allowance probability. The impact of direct engagement is a key factor for those navigating the difficult prosecution path in this specific art unit.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

19.3%
Allow Rate
-48.7% vs TC avg
81
Total Applications
+28.7%
Interview Lift
1796
Avg Prosecution Days
Based on 57 resolved cases, 2023–2026

Rejection Statute Breakdown

31.6%
§101 Eligibility
12.5%
§102 Novelty
28.7%
§103 Obviousness
18.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18025544 METHOD, APPARATUS AND DEVICE FOR ANALYZING GENOME METHYLATION SEQUENCING DATA, AND MEDIUM Non-Final OA BOE TECHNOLOGY GROUP CO., LTD.
17699439 SYSTEMS AND METHODS FOR IDENTIFYING EXON JUNCTIONS FROM SINGLE READS Final Rejection Life Technologies Corporation
18141199 MEDIA, METHODS, AND SYSTEMS FOR PROTEIN DESIGN AND OPTIMIZATION Non-Final OA BASF SE
18234101 Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-VEGF Non-Final OA Regeneron Pharmaceuticals, Inc.
18160578 METHOD OF IDENTIFYING PROPERTIES OF MOLECULES UNDER OPEN BOUNDARY CONDITIONS Non-Final OA Purdue Research Foundation
17699018 SYSTEMS AND METHODS FOR GENERATING, VISUALIZING AND CLASSIFYING MOLECULAR FUNCTIONAL PROFILES Final Rejection BostonGene Corporation
17992341 METHOD AND SYSTEM FOR ARTIFICIAL INTELLIGENCE-ASSISTED PREDICTION OF EMBRYO IMPLANTATION RATE IN ASSISTED REPRODUCTIVE TECHNOLOGY Non-Final OA NATIONAL CHENG KUNG UNIVERSITY
16719902 SYSTEMS AND METHODS FOR ESTIMATING CELL SOURCE FRACTIONS USING METHYLATION INFORMATION Final Rejection GRAIL, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month